<DOC>
	<DOCNO>NCT00718263</DOCNO>
	<brief_summary>This study evaluate safety tolerability nilotinib failure imatinib therapy imatinib therapy nilotinib failure .</brief_summary>
	<brief_title>Efficacy Safety Nilotinib Patients With Newly Diagnosed CML - CP ( Chronic Myelogenous Leukemia - Chronic Phase )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient ≥ 18 year age . 2 . ECOG 0 , 1 , 2 . 3 . Patients Ph+ CML fail treatment core protocol . 4 . Diagnosis chronic myelogenous leukemia cytogenetic confirmation Philadelphia chromosome ( 9 ; 22 ) translocation ( presence BCRABL review minimum 20 metaphase require ) . 5 . Adequate end organ function define : Total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 x ULN , Creatinine &lt; 1.5 x ULN , Serum amylase lipase ≤ 1.5 x ULN , Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor relate . 6 . Patients must follow laboratory value ( ≥ LLN ( low limit normal ) correct within normal limit supplement prior first dose study medication . ) : Potassium ≥ LLN , Magnesium ≥ LLN , Phosphorus ≥ LLN , Total calcium ( correct serum albumin ) ≥ LLN . Exclusion criterion : 1 . Previously document T315I mutation . 2 . Impaired cardiac function include one following : LVEF &lt; 45 % institutional low limit normal range ( whichever high ) determine locally read echocardiogram . Inability determine QT interval ECG . Complete leave bundle branch block . Use ventricularpaced pacemaker . Congenital long QT syndrome know family history long QT syndrome . History presence clinically significant ventricular atrial tachyarrhythmias .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>